US Stock Movers: Chemed surges on October 28—performance exceeds expectations, full-year EPS guidance remains strong, and Jefferies upgrades to Buy

Chemed’s Surge on October 28 Explained

Keywords: Earnings exceed expectations, strong full-year EPS guidance, Jefferies upgrades to Buy

1. On October 27, Chemed announced its Q3 2026 results, with revenue of $690.9 million, up 10.6% year-over-year; adjusted diluted earnings per share were $6.75, up 28.1% year-over-year and above the consensus estimate of $6.39.

2. On October 27, its VITAS hospice care business reported revenue of $457.4 million, up 12.2% year-over-year, with a 9.4% increase in average daily census; revenue from the Roto-Rooter plumbing and drain service business grew 7.5%.

3. On October 27, the company projected full-year 2026 adjusted earnings per share would reach the high end or slightly above its previous guidance range of $25.00 to $25.75.

4. On October 28, Jefferies upgraded Chemed from Hold to Buy and raised its price target from $475 to $620.

(Disclaimer: This content is summarized from publicly available information using AI technology, for reference only and does not constitute investment advice.)